Two get death, Abu Salem, another get life term in 1993 Mumbai blasts case

New Delhi, Apr 13: India's tally of positive COVID-19 cases rose to 9,152 following an increase of 796 cases in the last 24 hours, the Union Ministry of Health and Family Welfare said on Monday.

Out of the total number of cases, 7,987 patients are active cases while 857 cases have been cured/discharged and migrated.

With 35 deaths in the last 24 hours, the death toll mounted to 308.

According to the ministry, Maharashtra remained at the top with the total cases at 1,985, including 217 patients who have recovered/discharged and 149 patients died.

Delhi's tally of positive COVID-19 cases rose to 1,154 cases, including 27 recovered and 24 patients succumbing to the virus.

Tamil Nadu too reported 1,075 cases, including 50 recovered and 11 patients dead.

Meanwhile, four states have crossed the 500 mark with regards to the total number of cases as Rajasthan recorded 804 cases, Madhya Pradesh with 532 cases, Gujarat with 516 cases and Telangana with 504 cases, as per the ministry.

New Delhi, Mar 23: The central government has asked state governments to take strict action against violators of the coronavirus lockdown being enforced in 80 districts across the country.

An official statement released on Monday said there will be a total lockdown in 80 districts where coronavirus cases have been reported. The shutdown will end on March 31.

Delhi's borders will remain sealed during the lockdown, but essential services related to health, food, water and power supply will continue, and 25 per cent of the DTC buses will run to transport people associated with essential services.

Prime Minister Narendra Modi earlier on Monday appealed to state governments to ensure that rules and regulations of the coronavirus lockdown are enforced as he noted that many people were not taking the measure seriously.

"Many people are still not taking the lockdown seriously. Please save yourself, save your family, follow the instructions seriously. I request state governments to ensure rules and laws are followed," he said in a tweet in Hindi.

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.